Ergoteles LLC Sage Therapeutics, Inc. Transaction History

Ergoteles LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$40.65 - $59.54 $343,086 - $502,517	8,440 Added 31.41%	35,309 $1.66 Million
Q1 2023 May 10, 2023	SELL	$37.27 - $46.57 $864,589 - $1.08 Million	-23,198 Reduced 46.33%	26,869 $1.13 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $1.61 Million - $2.18 Million	50,067 New	50,067 $1.91 Million
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $589,478 - $877,403	-19,195 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $245,856 - $312,527	6,634 Added 52.81%	19,195 $817,000

Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $2.83 Million - $4.04 Million	-70,372 Reduced 84.85%	12,561 $557,000
Q2 2021 Aug 12, 2021	BUY	$54.88 - $79.29 $3.48 Million - $5.02 Million	63,330 Added 323.06%	82,933 $4.71 Million
Q1 2021 May 12, 2021	BUY	$70.65 - $96.76 $903,825 - $1.24 Million	12,793 Added 187.86%	19,603 $1.47 Million
Q4 2020 Feb 11, 2021	SELL	$58.41 - $89.06 $3.68 Million - $5.61 Million	-62,974 Reduced 90.24%	6,810 $589,000
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $2.87 Million - $4.36 Million	69,784 New	69,784 $4.27 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.